Implantica launches RefluxStop in US after FDA approval

• Implantica launched its RefluxStop implant in the US at the 2026 American Foregut Society meeting in Washington, D.C.
• Commercial rollout started following FDA PMA clearance, marking the company’s entry into the US GERD surgery market.
• Management shifted focus to a systematic US expansion, targeting adoption by major medical centers.
• The launch event drew more than 120 clinicians, with nearly 30 follow-up meetings to support new site onboarding.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Implantica AG published the original content used to generate this news brief on September 29, 2026, and is solely responsible for the information contained therein.